Connect with us

Business

Metal Gear Solid back with remake years after Kojima left Konami

Published

on

Metal Gear Solid back with remake years after Kojima left Konami


Tom GerkenTechnology reporter

Konami A video game character rendered in modern, high-quality graphics. She has long dirty blonde hair and blue eyes. She is wearing a jacket and has goggles hanging around her neck.Konami

EVA, one of the main characters in the remade game (image brightened from source)

Metal Gear is one of the best-selling video game series in history, shifting more than 60 million copies.

The series pioneered cinematics in gaming by blending cutting-edge cutscenes, voice acting and dynamic camera angles to create something that would have looked more at home on the big screen at the time.

Metal Gear tackled themes not commonly seen in games, such as nuclear disarmament and child soldiers, and posed philosophical questions while also leveraging offbeat humour.

The games would often break the fourth wall and ask players to find solutions to puzzles in unusual ways – such as looking on the back cover of the game’s physical box.

The series’ significant place in gaming history meant fans were stunned when its creator Hideo Kojima quit game publisher Konami in an acrimonious split in 2015.

One of gaming’s biggest titles was left directionless – and there’s been no game in the best-selling series since.

But now, a decade later, Konami has released a remake of the third game in the series: Metal Gear Solid Delta.

So what happened between Konami and Kojima, and how does the new game hold up without its original creator?

Why did Kojima leave Konami?

“The impact Metal Gear has had on game-making makes it one of the most heralded entertainment franchises in the world, and made Hideo Kojima one of the industry’s most famous creators,” industry expert Christopher Dring told the BBC.

With such success, you might think it was a match made in heaven, but there were issues bubbling under the surface.

While nothing has been said publicly, one generally accepted theory behind the split relates to the spiralling cost of 2015’s Metal Gear Solid V, estimated by some at more than $80m (£59m) – a very significant development cost at the time.

It is not known exactly what happened between Konami and Kojima, but the studio was clearly fed up with the amount of money he was spending to make a single game – with Kojima’s internal studio actually removed from promotional materials for Metal Gear Solid V at the time.

Konami got the game out the door, but it seemed to be scaled back from its original vision despite the high cost, with repeated levels and a third chapter that never emerged.

Even so, the game still received excellent reviews and won several awards, but the rift between company and creator seemed unfixable.

And in an act that proved highly controversial – and perhaps shows how heated things had become behind the scenes – when Metal Gear Solid V won an award, Konami informed the developer he was not allowed to collect it.

Getty Images Hideo Kojima. He has black hair in a short cut and wears large black glasses. He is smiling while he talks at a conference. He is wearing a trim black jacket and black t-shirt.Getty Images

Hideo Kojima has become one of the most famous names in gaming over the past three decades

A few months later, Kojima was gone, and in the years that followed, his former studio pivoted.

“Konami shifted its strategy for a while, away from console games, and focused its efforts on the amusements markets, things like pachinko machines,” Mr Dring said.

“They also focused increasingly on mobile.”

It meant Konami’s other classic franchises like Castlevania and Silent Hill also went without new games for a decade.

Meanwhile, Kojima’s new studio signed a blockbuster deal with Sony to develop the monster hit Death Stranding for PlayStation, followed by a sequel this year.

Why a remake now?

Gaming has pivoted towards remakes in recent years.

High-profile games like Resident Evil 4, Final Fantasy VII and Demon’s Souls, all classics in their day, have been remade with the benefits of modern graphics and game design to big fanfare – and strong sales figures.

“It’s a hugely lucrative and growing sector,” said Mr Dring.

“The industry is getting older, gamers are entering middle age and are nostalgic for classic titles.

Mr Drings points out that one of the best-selling games of the year so far is Elder Scrolls V: Oblivion Remastered, a remake of a classic Role-Playing Game (RPG) from 2007, selling millions of copies since its release in April.

Konami has begun a return to publishing games by focusing in this area, with a Silent Hill remake coming last year and a new Survival Kids game released earlier in 2025.

So it is a potentially lucrative move – but is Metal Gear Solid 3: Snake Eater the right game to remake?

Konami A jungle scene from a video game. It is instantly recognisable as an older video game, with blocky rocks and pixel-y trees.Konami

A jungle scene from Metal Gear Solid 3’s original release in 2004. Believe it or not, these were considered ground-breaking graphics at the time

Fans of the series told the BBC Metal Gear Solid 3 was chosen for good reason.

YouTuber Zak Ras said there was “immense significance” behind the game.

“Most people will say their favourite entry to the series is either Metal Gear Solid 1 or 3,” he said.

“Story-wise, given that it’s the first prequel set at the very beginning of the series timeline, it’s one of the few entries you can go into completely blind with absolutely no required knowledge of the series, other than very first Metal Gear from 1987.”

Ras said Metal Gear Solid 3 struck a good balance between gameplay and cinematic storytelling, making it a good choice for people who have never played a game in the series before.

For example, the game opens with an introduction heavily influenced by James Bond films, meaning new fans are eased into the series’ weirder elements.

And the brothers behind PythonSelkan Studios – known as Python & Selkan to their 122,000 YouTube subscribers – agreed.

“Completing the game was an incredible experience in itself,” they said. “Snake Eater’s gut-wrenching ending is what stood out most, leaving an impact on us that no other game had ever left before.”

“This game holds a special place in our hearts,” they added.

Metal Gear without Kojima

The brothers said, as lifelong fans of the series, they were “incredibly excited” by the announcement.

The pair are currently playing the remake, and have been “very impressed” by its improved graphics and audio.

They described the game as a “truly a faithful recreation”, adding that it improved “the essence of the original without changing its fundamental structure”.

Konami A jungle scene rendered in a video game. In the foreground, photo-realistic plants grow in front of a large tree. Several trees in the background are broken up by a beam of light.Konami

The game’s lush jungle setting has benefitted from two decades of improvements in graphical fidelity

So far so good for Metal Gear Solid without Hideo Kojima – which Ras put down to the game being true to the original.

One example he highlights is that the voice performances have been kept the same, and players can choose whether to use the original control scheme or a more modern take.

“There’s no doubt it is Kojima’s directorial ‘genes’ that are being dominantly expressed here,” he said.

“Kojima expressed a desire to move on from Metal Gear since as early as MGS2 and leave the series in the hands of others to continue.

“It may have taken him another 14 years and five director credits for that to happen, but it is now reality.”

And however the remake fares with fans, one household won’t be picking up a new copy – Kojima himself has laughed off the suggestion that he would play the new game.

A green promotional banner with black squares and rectangles forming pixels, moving in from the right. The text says: “Tech Decoded: The world’s biggest tech news in your inbox every Monday.”



Source link

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Business

What’s happening to gas prices and how could it affect you?

Published

on

What’s happening to gas prices and how could it affect you?



Analysts fear the disruption to supply could continue for longer than initially thought.



Source link

Continue Reading

Business

Bank of England ‘ready to act’ on rising prices as interest rates on hold

Published

on

Bank of England ‘ready to act’ on rising prices as interest rates on hold



Policymakers vote unanimously to hold rates at 3.75% after the Iran war prompts a sea-change in the debate over borrowing costs.



Source link

Continue Reading

Business

Eli Lilly’s next-generation obesity drug retatrutide clears first late-stage diabetes trial

Published

on

Eli Lilly’s next-generation obesity drug retatrutide clears first late-stage diabetes trial


Eli Lilly on Thursday said its next-generation obesity drug retatrutide cleared its first late-stage trial on Type 2 diabetes patients, helping them manage their blood sugar levels and lose weight. 

The drug lowered hemoglobin A1c — a key measure of blood sugar levels — by an average of 1.7% to 2% across different doses at 40 weeks compared to placebo, meeting the study’s main goal. Patients started the trial with an A1c in the range of 7% to 9.5%, and were not taking other diabetes medications. 

Retatrutide also met the study’s second goal, helping patients at the highest dose lose an average of 16.8% of their weight, or 36.6 pounds, at 40 weeks, when evaluating only patients who stayed on the drug. When analyzing all participants, including those who discontinued treatment, the highest dose of the drug helped patients lose 15.3% of their weight.

Patients with Type 2 diabetes historically struggle to lose weight, so Lilly is “very excited” to see that the drug led to both a competitive drop in blood sugar levels and significant weight loss, Ken Custer, president of Lilly Cardiometabolic Health, said in an interview. 

The company was also “very pleased” with the relatively low discontinuation rates due to side effects, which were up to 5%, he added.

They are the second late-stage results to date on retatrutide, which works differently from existing injections and appears to be more effective, at least for weight loss. Lilly is betting big on retatrutide as the next pillar of its obesity portfolio after its blockbuster weight loss injection Zepbound and its upcoming pill, orforglipron. 

But Lilly has yet to file for approval for the drug for obesity or diabetes. The company expects to report findings from seven additional phase three trials on the drug by the end of the year. 

There are no head-to-head trials of retatrutide against other drugs, making it difficult to directly compare efficacy. 

Still, retatrutide’s A1C reduction doesn’t appear to be the greatest Lilly has seen within its portfolio: The highest dose of Zepbound lowered the measure by more than 2% at 40 weeks in two separate trials on diabetes patients.

But Custer said retatrutide’s A1C reduction is still “very, very strong” compared to other diabetes medications that don’t target gut hormones. 

He also said that having options in the obesity and diabetes space will be important because “not everybody is going to be helped with or satisfied with the same treatment.” Choosing which drug to take will depend on “individualized tailoring of solutions and patients,” particularly earlier in their diabetes treatment, he added. 

For example, Custer said patients who want to regulate their blood sugar could benefit from either Zepbound or retatrutide. But if they are looking to lose more weight, the latter might be a better option, he said.

In the two separate diabetes trials, Zepbound helped patients lose slightly less weight than retatrutide did. In one study called SURPASS-2, the highest dose of Zepbound helped patients lose an average of 13.1% of their weight at 40 weeks. In the other study, SURPASS-1, the highest dose helped patients lose an average of 11% of their weight at the 40-week mark.

Retatrutide’s safety profile was similar to other injectable diabetes and obesity drugs, primarily causing gastrointestinal side effects. Around 26.5% of patients on the highest dose experienced nausea, while roughly 22.8% and 17.6% had diarrhea and vomiting, respectively. 

Low rates of patients experienced dysesthesia, which is an unpleasant nerve sensation.

Dubbed the “triple G” drug, retatrutide works by mimicking three hunger-regulating hormones – GLP-1, GIP and glucagon – rather than just one or two like existing treatments. That appears to have more potent effects on a person’s appetite and satisfaction with food than other treatments.

Tirzepatide, the active ingredient in Zepbound, mimics GLP-1 and GIP. Novo Nordisk’s semaglutide, the active ingredient in Wegovy, mimics only GLP-1.

As retatrutide inches closer to the market, Novo is racing to catch up to Lilly. In March 2025, Novo said it agreed to pay up to $2 billion for the rights to an early experimental drug from the Chinese pharmaceutical company United Laboratories International. 

Novo’s newly acquired drug is a clear potential competitor to retatrutide because it similarly uses a three-pronged approach to promoting weight loss and regulating blood sugar. But Novo’s treatment is much earlier in development, meaning it will take several years before it reaches patients.



Source link

Continue Reading

Trending